'Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis'; this LANCET study put out February 2023 should have put SUPERIOR natural immunity question to rest

Along with my seminal paper 2 years now on superiority of natural immunity over vaccine immunity: https://brownstone.org/articles/research-studies-affirm-naturally-acquired-immunity/; but it did not

This potent LANCET published review was sidelined as if it did not exist yet the conclusion was staggering: “Protection from past infection against re-infection from pre-omicron variants was very high and remained high even after 40 weeks. Protection was substantially lower for the omicron BA.1 variant and declined more rapidly over time than protection against previous variants. Protection from severe disease was high for all variants. The immunity conferred by past infection should be weighed alongside protection from vaccination when assessing future disease burden from COVID-19, providing guidance on when individuals should be vaccinated”.

‘identified a total of 65 studies from 19 different countries. Our meta-analyses showed that protection from past infection and any symptomatic disease was high for ancestral, alpha, beta, and delta variants, but was substantially lower for the omicron BA.1 variant. Pooled effectiveness against re-infection by the omicron BA.1 variant was 45·3% (95% uncertainty interval [UI] 17·3–76·1) and 44·0% (26·5–65·0) against omicron BA.1 symptomatic disease. Mean pooled effectiveness was greater than 78% against severe disease (hospitalisation and death) for all variants, including omicron BA.1. Protection from re-infection from ancestral, alpha, and delta variants declined over time but remained at 78·6% (49·8–93·6) at 40 weeks. Protection against re-infection by the omicron BA.1 variant declined more rapidly and was estimated at 36·1% (24·4–51·3) at 40 weeks. On the other hand, protection against severe disease remained high for all variants, with 90·2% (69·7–97·5) for ancestral, alpha, and delta variants, and 88·9% (84·7–90·9) for omicron BA.1 at 40 weeks.’

Omicron had sufficient mutations that it presented almost as a novel virus and caused an immune rechallenge. Yet still immune systems have dealt with it effectively.

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)02465-5/fulltext#%20

‘results show that high levels of protection—on average greater than 85%—are present for ancestral, alpha, delta, and beta variants across all three outcomes (infection, any symptomatic disease, and severe disease). The analysis shows the substantially reduced level of protection against re-infection or any symptomatic disease to less than 55% for the omicron variant’